

Streamline
Health[®]

First Quarter 2020 Earnings
Nasdaq: STRM

Disclosure Statement

SAFE HARBOR STATEMENT: FORWARD-LOOKING DISCLOSURE


This presentation contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, based on current management expectations. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and that can cause Streamline Health’s actual results to differ. We caution you therefore to not place undue reliance on such statements.

Actual results might differ materially from these statements due to a number of risks and uncertainties. Risks that may contribute to the uncertain nature of these statements are described in Streamline Health’s periodic filings made with Securities and Exchange Commission. Special attention is directed to the portions of those documents entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Streamline Health undertakes no obligation to update any forward-looking statements or relevant risks, except as may be required by law.


TRADEMARKS

Product or company names referenced herein may be trademarks or registered trademarks of their respective owners


1Q20 Highlights



Completed sale of legacy ECM business late February




COVID-19 negatively impacted revenue, primarily due to delayed customer decisions




Successfully closed a three-year eValuator contract with a **1,200-bed** teaching hospital in the Midwest


Operational Improvements



COVID-19 has drawn increased awareness to the need for revenue integrity tools





R&D team has been focused on improving key elements of eValuator, while Product Management added **30+ COVID-related rule sets**




Launched new Customer Success organization to ensure selling efforts are well-supported


Bookings & Pipeline Update



Project return to achieving **\$2-\$3M** quarterly bookings target



Pipeline contains **\$62M** of bookings opportunities across 89 prospects



16 eValuator prospects received an aggregate **\$422M** of CARES funding

Financial Results – Income Statement


	Three Months Ended April 30, 2020	Three Months Ended April 30, 2019
Revenue	\$2.8M	\$3.2M
Operating Expenses	\$4.4M	\$4.0M
Loss From Continuing Operations	(\$1.0M)	(\$0.6M)
Net Income	\$3.7M	\$0.3M
Adj. EBITDA*	(\$0.6M)	(\$0.3M)

*Streamline Health defines "adjusted EBITDA" as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense of tangible and intangible assets, stock-based compensation expense, significant non-recurring operating expenses, and transactional related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses, associate inducements, and professional and advisory fees.


Financial Results – Balance Sheet

	As of April 30, 2020	As of January 31, 2020
Cash & Cash Equivalents	\$6.6M	\$1.6M
Total Current Assets	\$8.8M	\$6.7M
Total Current Liabilities	\$6.6M	\$15.6M
Total Bank Debt Outstanding	\$0.0M	\$3.8M


Looking Forward



Anticipate sequentially lower revenue of \$2.3M in 2Q-2020, and sequentially higher revenues for the remainder of FY-2020 and beyond.




Expect higher Adjusted EBITDA loss in 2020 due to the impact of COVID-19




Believe current cash on hand is sufficient to enable the company to grow through 2021

A Growing Company in a Growing Market




Mid-revenue cycle management and clinical documentation improvement (CDI) market is expected to grow to **\$4.5B by 2023**, from \$3.1B in 2018*



The eValuator Revenue Integrity Program, Abstracting and CDI Technologies are well positioned in this market

*Research and Markets, Mid-Revenue Cycle Management/Clinical Documentation Improvement Market by Product & Service (Clinical Documentation, Clinical Coding (NLP, Structure Input), Charge Capture, CDI, DRG, Pre-Bill Review), End User, and Region - Global Forecast to 2023



Streamline
Health[®]

First Quarter 2020 Earnings
Nasdaq: STRM